Literature DB >> 30551984

Keeping the Heart Fitm2 during Chemotherapy.

Joep E C Eding1, Eva van Rooij2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30551984      PMCID： PMC6320341          DOI： 10.1016/j.ymthe.2018.12.002

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  17 in total

1.  Effects of PPARα/PGC-1α on the energy metabolism remodeling and apoptosis in the doxorubicin induced mice cardiomyocytes in vitro.

Authors:  Yongyao Yang; Hongming Zhang; Xiaoyan Li; Tianhe Yang; Qingan Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  miR-212/132 Cluster Modulation Prevents Doxorubicin-Mediated Atrophy and Cardiotoxicity.

Authors:  Shashi Kumar Gupta; Ankita Garg; Petros Avramopoulos; Stefan Engelhardt; Katrin Streckfuss-Bömeke; Sandor Batkai; Thomas Thum
Journal:  Mol Ther       Date:  2018-11-13       Impact factor: 11.454

Review 3.  Cardioprotective interventions for cancer patients receiving anthracyclines.

Authors:  E C van Dalen; H N Caron; H O Dickinson; L C M Kremer
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

4.  Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies).

Authors:  Xavier Bosch; Montserrat Rovira; Marta Sitges; Ariadna Domènech; José T Ortiz-Pérez; Teresa M de Caralt; Manuel Morales-Ruiz; Rosario J Perea; Mariano Monzó; Jordi Esteve
Journal:  J Am Coll Cardiol       Date:  2013-04-10       Impact factor: 24.094

Review 5.  MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles.

Authors:  Eva van Rooij; Eric N Olson
Journal:  Nat Rev Drug Discov       Date:  2012-10-19       Impact factor: 84.694

6.  The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy.

Authors:  Ahmet Ucar; Shashi K Gupta; Jan Fiedler; Erdem Erikci; Michal Kardasinski; Sandor Batkai; Seema Dangwal; Regalla Kumarswamy; Claudia Bang; Angelika Holzmann; Janet Remke; Massimiliano Caprio; Claudia Jentzsch; Stefan Engelhardt; Sabine Geisendorf; Carolina Glas; Thomas G Hofmann; Michelle Nessling; Karsten Richter; Mario Schiffer; Lucie Carrier; L Christian Napp; Johann Bauersachs; Kamal Chowdhury; Thomas Thum
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

7.  MicroRNA-208a Silencing Attenuates Doxorubicin Induced Myocyte Apoptosis and Cardiac Dysfunction.

Authors:  Hasahya Tony; Kunwu Yu; Zeng Qiutang
Journal:  Oxid Med Cell Longev       Date:  2015-06-07       Impact factor: 6.543

8.  Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol.

Authors:  Geeta Gulati; Siri Lagethon Heck; Anne Hansen Ree; Pavel Hoffmann; Jeanette Schulz-Menger; Morten W Fagerland; Berit Gravdehaug; Florian von Knobelsdorff-Brenkenhoff; Åse Bratland; Tryggve H Storås; Tor-Arne Hagve; Helge Røsjø; Kjetil Steine; Jürgen Geisler; Torbjørn Omland
Journal:  Eur Heart J       Date:  2016-02-21       Impact factor: 29.983

Review 9.  Anthracycline Chemotherapy and Cardiotoxicity.

Authors:  John V McGowan; Robin Chung; Angshuman Maulik; Izabela Piotrowska; J Malcolm Walker; Derek M Yellon
Journal:  Cardiovasc Drugs Ther       Date:  2017-02       Impact factor: 3.727

10.  2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).

Authors:  Jose Luis Zamorano; Patrizio Lancellotti; Daniel Rodriguez Muñoz; Victor Aboyans; Riccardo Asteggiano; Maurizio Galderisi; Gilbert Habib; Daniel J Lenihan; Gregory Y H Lip; Alexander R Lyon; Teresa Lopez Fernandez; Dania Mohty; Massimo F Piepoli; Juan Tamargo; Adam Torbicki; Thomas M Suter
Journal:  Eur Heart J       Date:  2016-08-26       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.